Skip to main content
Erschienen in: Digestive Diseases and Sciences 10/2007

01.10.2007 | Original Article

Demonstration of Low-Regulatory CD25High+CD4+ and High-Pro-inflammatory CD28CD4+ T-Cell Subsets in Patients with Ulcerative Colitis: Modified by Selective Granulocyte and Monocyte Adsorption Apheresis

verfasst von: Yoko Yokoyama, Ken Fukunaga, Yoshihiro Fukuda, Katsuyuki Tozawa, Koji Kamikozuru, Kunio Ohnishi, Takeshi Kusaka, Tadashi Kosaka, Nobuyuki Hida, Yoshio Ohda, Hiroto Miwa, Takayuki Matsumoto

Erschienen in: Digestive Diseases and Sciences | Ausgabe 10/2007

Einloggen, um Zugang zu erhalten

Abstract

Low-CD25High+CD4+, a subset of regulatory CD25+CD4+ T cells and high-inflammatory CD28CD4+ T cells can exacerbate ulcerative colitis (UC). This study sought to investigate the frequency of CD25High+CD4+ and CD28CD4+ T cells in patients with UC and the changes in these cells during Adacolumn granulocyte and monocyte adsorption apheresis (GMA). Subjects were 12 patients with active UC, 11 with quiescent UC, and 14 healthy volunteers (HVs). The mean clinical activity index was 15.7 ± 2.2 in active UC and 4.5 ± 1.1 in quiescent UC. Peripheral blood samples were stained with CD4, CD25, and CD28 antibodies for flow cytometry. Patients with active UC received GMA and blood samples were examined before and after the first GMA session. Patients with active UC (P < 0.04) or quiescent UC (P < 0.02) had a higher percentage of CD28D4+T cells compared with HVs, while the percentage of CD28+CD4+ T cells was lower in both UC groups compared with HVs (P = 0.03 and P < 0.02). Patients with active UC had a lower percentage of CD25High+CD4+T cells compared with quiescent UC patients (P < 0.001). A significant increase in CD25High+CD4+ T cells was associated with GMA (P < 0.03). Low CD25High+CD4+ and high CD28CD4+ are prominent features in UC. The increase in CD25High+CD4+ T cells induced by GMA should contribute to improved immune function. Additional studies are warranted, since a low frequency of CD25High+CD4+ and a high frequency of CD28CD4+ expressing T cells might be a predictor of clinical response to GMA.
Literatur
1.
Zurück zum Zitat Isaacs KL, Lewis JD, Sandborn WJ (2005) State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis 11:S3–S12PubMedCrossRef Isaacs KL, Lewis JD, Sandborn WJ (2005) State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis 11:S3–S12PubMedCrossRef
2.
Zurück zum Zitat Kanai K, Watanabe M (2005) Clinical application of human CD4+CD25+ regulatory T cells for the treatment of inflammatory bowel disease. Expert Opin Biol Ther 5:451–462PubMedCrossRef Kanai K, Watanabe M (2005) Clinical application of human CD4+CD25+ regulatory T cells for the treatment of inflammatory bowel disease. Expert Opin Biol Ther 5:451–462PubMedCrossRef
3.
Zurück zum Zitat Schmidt D, Goronzy JJ, Weyand CM (1996) CD4+CD7-CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest 97:2027–2037PubMedCrossRef Schmidt D, Goronzy JJ, Weyand CM (1996) CD4+CD7-CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest 97:2027–2037PubMedCrossRef
4.
Zurück zum Zitat Lenschow DJ, Walunas TL, Bluestone JA (1996) CD28/B7 system of T cell costimulation. Annu Rev Immunol 14:233–258PubMedCrossRef Lenschow DJ, Walunas TL, Bluestone JA (1996) CD28/B7 system of T cell costimulation. Annu Rev Immunol 14:233–258PubMedCrossRef
5.
Zurück zum Zitat Martens P, Goronzy JJ, Schaid D (1997) Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arth Rheum 40:1106–1114CrossRef Martens P, Goronzy JJ, Schaid D (1997) Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arth Rheum 40:1106–1114CrossRef
6.
Zurück zum Zitat Markovic-Plese S, Cortese I, Wandinger KP (2001) CD4+CD28- costimulation-independent T cells in multiple sclerosis. J Clin Invest 108:1185–1194PubMedCrossRef Markovic-Plese S, Cortese I, Wandinger KP (2001) CD4+CD28- costimulation-independent T cells in multiple sclerosis. J Clin Invest 108:1185–1194PubMedCrossRef
7.
Zurück zum Zitat De Tena JG, Manzano L, Leal JC (2004) Active Crohn’s disease patients show a distinctive expansion of circulating memory CD4+CD45RO+CD28null T cells. J Clin Immunol 24:185–196CrossRef De Tena JG, Manzano L, Leal JC (2004) Active Crohn’s disease patients show a distinctive expansion of circulating memory CD4+CD45RO+CD28null T cells. J Clin Immunol 24:185–196CrossRef
8.
Zurück zum Zitat Gershon RK (1975) A disquisition on suppressor T cells. Transplant Rev 26:170–185PubMed Gershon RK (1975) A disquisition on suppressor T cells. Transplant Rev 26:170–185PubMed
9.
Zurück zum Zitat Sakaguchi S, Sakaguchi N, Shimizu J (2001) Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18–32PubMedCrossRef Sakaguchi S, Sakaguchi N, Shimizu J (2001) Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18–32PubMedCrossRef
10.
Zurück zum Zitat Curotto de Lafaille MA, Lafaille JJ (2002) CD4+ regulatory T cells in autoimmunity and allergy. Curr Opin Immunol 14:771–778PubMedCrossRef Curotto de Lafaille MA, Lafaille JJ (2002) CD4+ regulatory T cells in autoimmunity and allergy. Curr Opin Immunol 14:771–778PubMedCrossRef
11.
Zurück zum Zitat Annacker O, Pimenta-Araujo R (2001) CD25+CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol 166:3008–3018PubMed Annacker O, Pimenta-Araujo R (2001) CD25+CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol 166:3008–3018PubMed
12.
Zurück zum Zitat Saniabadi AR, Hanai H, Lofberg R (2003) Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher 7:48–59CrossRef Saniabadi AR, Hanai H, Lofberg R (2003) Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher 7:48–59CrossRef
13.
Zurück zum Zitat Kashiwagi N, Sugimura K, Koiwai H, Saniabadi A (2002) Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 6:1334–1341CrossRef Kashiwagi N, Sugimura K, Koiwai H, Saniabadi A (2002) Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 6:1334–1341CrossRef
14.
Zurück zum Zitat Shimoyama T, Sawada K, Hiwatashi N (2001) Safety and efficacy of granulocytes and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 16:1–9PubMedCrossRef Shimoyama T, Sawada K, Hiwatashi N (2001) Safety and efficacy of granulocytes and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 16:1–9PubMedCrossRef
15.
Zurück zum Zitat Suzuki Y, Yoshimura N, Saniabadi AR (2004) Selective granulocytes and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 49:565–571PubMedCrossRef Suzuki Y, Yoshimura N, Saniabadi AR (2004) Selective granulocytes and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 49:565–571PubMedCrossRef
16.
Zurück zum Zitat Hanai H, Watanabe F, Takeuchi K (2003) Leukcocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective uncontrolled pilot study. Clin Gastroenterol Hepatol 1:28–35PubMedCrossRef Hanai H, Watanabe F, Takeuchi K (2003) Leukcocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective uncontrolled pilot study. Clin Gastroenterol Hepatol 1:28–35PubMedCrossRef
17.
Zurück zum Zitat Lichtiger S, Present DH, Kornbluth A (1994) Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330:1841–1845PubMedCrossRef Lichtiger S, Present DH, Kornbluth A (1994) Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330:1841–1845PubMedCrossRef
18.
Zurück zum Zitat Saniabadi AR, Hanai H, Suzuki Y (2005) Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: An adjunct or an alternative to drug therapy? J Clin Apher 20:171–184PubMedCrossRef Saniabadi AR, Hanai H, Suzuki Y (2005) Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: An adjunct or an alternative to drug therapy? J Clin Apher 20:171–184PubMedCrossRef
19.
Zurück zum Zitat Hiraishi K, Takeda Y, Shiobara N (2003) Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial 7:334–340PubMedCrossRef Hiraishi K, Takeda Y, Shiobara N (2003) Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial 7:334–340PubMedCrossRef
20.
Zurück zum Zitat D’Arrigo C, Candal-Couto JJ, Greer M (1993) Human neutrophil Fc receptor-mediated adhesion under flow: a hollow fiber model of intravascular arrest. Clin Exp Immunol 100:173–179CrossRef D’Arrigo C, Candal-Couto JJ, Greer M (1993) Human neutrophil Fc receptor-mediated adhesion under flow: a hollow fiber model of intravascular arrest. Clin Exp Immunol 100:173–179CrossRef
21.
Zurück zum Zitat Kanke K, Nakano M, Hiraishi H (2004) Evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liv Dis 36:512–518CrossRef Kanke K, Nakano M, Hiraishi H (2004) Evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liv Dis 36:512–518CrossRef
22.
Zurück zum Zitat Naganuma M, Funakoshi S, Sakuraba A (2004) Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 10:251–257PubMedCrossRef Naganuma M, Funakoshi S, Sakuraba A (2004) Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 10:251–257PubMedCrossRef
23.
Zurück zum Zitat Yamamoto T, Umegae S, Kitagawa T (2004) Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther 20:783–792PubMedCrossRef Yamamoto T, Umegae S, Kitagawa T (2004) Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther 20:783–792PubMedCrossRef
24.
Zurück zum Zitat Domenech E, Hinojosa J, Esteve-Comas M, Spanish Group for the Study of Crohn’s Disease and Ulcerative Colitis (GETECCU) (2004) Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther 20:1347–1352PubMedCrossRef Domenech E, Hinojosa J, Esteve-Comas M, Spanish Group for the Study of Crohn’s Disease and Ulcerative Colitis (GETECCU) (2004) Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther 20:1347–1352PubMedCrossRef
25.
Zurück zum Zitat Suzuki Y, Yoshimura N, Fukuda K, Shirai K, Saito Y, Saniabadi AR (2006) A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci Sep 27 Suzuki Y, Yoshimura N, Fukuda K, Shirai K, Saito Y, Saniabadi AR (2006) A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci Sep 27
26.
Zurück zum Zitat McCarthy DA, Rampton DS, Liu Y-C (1991) Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol 86:489–493PubMedCrossRef McCarthy DA, Rampton DS, Liu Y-C (1991) Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol 86:489–493PubMedCrossRef
27.
Zurück zum Zitat Rugtveit J, Brandtzaeg P, Halstensen TS (1994) Increased macrophage subsets in inflammatory bowel disease:apparent recruitment from peripheral blood monocytes. Gut 35:669–674PubMed Rugtveit J, Brandtzaeg P, Halstensen TS (1994) Increased macrophage subsets in inflammatory bowel disease:apparent recruitment from peripheral blood monocytes. Gut 35:669–674PubMed
28.
Zurück zum Zitat Meuret G, Bitzi A, Hammer B (1978) Macrophage turnover in Crohn’s disease and ulcerative colitis. Gastroenterology 74:501–503PubMed Meuret G, Bitzi A, Hammer B (1978) Macrophage turnover in Crohn’s disease and ulcerative colitis. Gastroenterology 74:501–503PubMed
29.
Zurück zum Zitat Brannigan AE, O’Connell PR, Hurley H (2000) Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock 13:361–366PubMed Brannigan AE, O’Connell PR, Hurley H (2000) Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock 13:361–366PubMed
30.
Zurück zum Zitat Cassatella MA (1995) The production of cytokines by polymorphonuclear neutrophils. Immunol Today 16:21–26PubMedCrossRef Cassatella MA (1995) The production of cytokines by polymorphonuclear neutrophils. Immunol Today 16:21–26PubMedCrossRef
31.
Zurück zum Zitat Nikolaus S, Bauditz J, Gionchetti P (1998) Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation. Gut 42:470–476PubMedCrossRef Nikolaus S, Bauditz J, Gionchetti P (1998) Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation. Gut 42:470–476PubMedCrossRef
32.
Zurück zum Zitat Mahida YR (2000) The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 6:21–33PubMedCrossRef Mahida YR (2000) The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 6:21–33PubMedCrossRef
33.
Zurück zum Zitat Hanauer SB (2006) Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 12:S3–S9PubMedCrossRef Hanauer SB (2006) Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 12:S3–S9PubMedCrossRef
34.
Zurück zum Zitat Allison MC, Dhillon AP, Lewis WG (eds) (1998) Inflammatory bowel disease. Mosby, London, pp 15–95 Allison MC, Dhillon AP, Lewis WG (eds) (1998) Inflammatory bowel disease. Mosby, London, pp 15–95
35.
Zurück zum Zitat Tibble JA, Sigthorsson G, Bridger D (2000) Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119:15–22PubMedCrossRef Tibble JA, Sigthorsson G, Bridger D (2000) Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119:15–22PubMedCrossRef
36.
Zurück zum Zitat Limburg P, David M, Ahlquist A, Sandborn WJ (2000) Faecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhoea referred for colonoscopy. Am J Gastroenterol 95:2831–2837PubMedCrossRef Limburg P, David M, Ahlquist A, Sandborn WJ (2000) Faecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhoea referred for colonoscopy. Am J Gastroenterol 95:2831–2837PubMedCrossRef
37.
Zurück zum Zitat Kuchroo V, Das MP, Brown JA (1995) B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 development pathways: application to autoimmune disease therapy. Cell 80:707–718PubMedCrossRef Kuchroo V, Das MP, Brown JA (1995) B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 development pathways: application to autoimmune disease therapy. Cell 80:707–718PubMedCrossRef
38.
Zurück zum Zitat Lenschow DJ, Ho SC, Satter H (1995) Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 181:1145–1155PubMedCrossRef Lenschow DJ, Ho SC, Satter H (1995) Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 181:1145–1155PubMedCrossRef
39.
Zurück zum Zitat Strober W, Fuss IJ, Blumberg RS (2002) The immunology of mucosal models of inflammation. Annu Rev Immunol 20:495–549PubMedCrossRef Strober W, Fuss IJ, Blumberg RS (2002) The immunology of mucosal models of inflammation. Annu Rev Immunol 20:495–549PubMedCrossRef
40.
Zurück zum Zitat Karandikar NJ, Vanderlugt CL, Walunas T (1996) CTLA-4: a negative regulator of autoimmune disease. J Exp Med 184:783–788PubMedCrossRef Karandikar NJ, Vanderlugt CL, Walunas T (1996) CTLA-4: a negative regulator of autoimmune disease. J Exp Med 184:783–788PubMedCrossRef
41.
Zurück zum Zitat Rulifson IC, Sperling AI, Fields PE, Fitch FW, Bluestone JA (1997) CD28 costimulation promotes the production of Th2 cytokines. J Immunol 158:658–665PubMed Rulifson IC, Sperling AI, Fields PE, Fitch FW, Bluestone JA (1997) CD28 costimulation promotes the production of Th2 cytokines. J Immunol 158:658–665PubMed
42.
Zurück zum Zitat Shahinian A, Pfeffer KP, Lee TM (1993) Differential T cell costimulatory requirements in CD28-deficient mice. Science 261:609–612PubMedCrossRef Shahinian A, Pfeffer KP, Lee TM (1993) Differential T cell costimulatory requirements in CD28-deficient mice. Science 261:609–612PubMedCrossRef
43.
Zurück zum Zitat Green JM, Noel PJ, Sperling AI (1994) Absence of B7-dependent responses in CD28-deficient mice. Immunity 1:501–508PubMedCrossRef Green JM, Noel PJ, Sperling AI (1994) Absence of B7-dependent responses in CD28-deficient mice. Immunity 1:501–508PubMedCrossRef
44.
Zurück zum Zitat Read S, Malmstom V, Powrie F (2001) Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J Exp Med 192:295–302CrossRef Read S, Malmstom V, Powrie F (2001) Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J Exp Med 192:295–302CrossRef
45.
Zurück zum Zitat Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA (2001) CD4+CD25high regulatory cells in human peripheral blood. J Immunol 31:1247–1253CrossRef Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA (2001) CD4+CD25high regulatory cells in human peripheral blood. J Immunol 31:1247–1253CrossRef
46.
Zurück zum Zitat Makita S, Kanai T, Oshima S (2004) CD4+CD25bright T cells in human intestinal lamia propria as regulatory cells. J Immunol 173:3119–3130PubMed Makita S, Kanai T, Oshima S (2004) CD4+CD25bright T cells in human intestinal lamia propria as regulatory cells. J Immunol 173:3119–3130PubMed
47.
Zurück zum Zitat Kashiwagi N, Sugimura K, Koiwai H, Saniabadi A (2002) Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 6:1334–1341CrossRef Kashiwagi N, Sugimura K, Koiwai H, Saniabadi A (2002) Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 6:1334–1341CrossRef
48.
Zurück zum Zitat Andoh A, Tsujikawa T, Inatomi O, Deguchi Y, Hata K, Kitoh K, Sasaki M, Mitsuyama K, Fujiyama Y (2005) Suppression of inflammatory cytokines secretion by granulocyte/monocytes adsorptive apheresis in active ulcerative colitis. Ther Apher Dial 2:123–127CrossRef Andoh A, Tsujikawa T, Inatomi O, Deguchi Y, Hata K, Kitoh K, Sasaki M, Mitsuyama K, Fujiyama Y (2005) Suppression of inflammatory cytokines secretion by granulocyte/monocytes adsorptive apheresis in active ulcerative colitis. Ther Apher Dial 2:123–127CrossRef
Metadaten
Titel
Demonstration of Low-Regulatory CD25High+CD4+ and High-Pro-inflammatory CD28−CD4+ T-Cell Subsets in Patients with Ulcerative Colitis: Modified by Selective Granulocyte and Monocyte Adsorption Apheresis
verfasst von
Yoko Yokoyama
Ken Fukunaga
Yoshihiro Fukuda
Katsuyuki Tozawa
Koji Kamikozuru
Kunio Ohnishi
Takeshi Kusaka
Tadashi Kosaka
Nobuyuki Hida
Yoshio Ohda
Hiroto Miwa
Takayuki Matsumoto
Publikationsdatum
01.10.2007
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 10/2007
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9560-z

Weitere Artikel der Ausgabe 10/2007

Digestive Diseases and Sciences 10/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.